Perrigo Company plc Ordinary Shares (PRGO): Price and Financial Metrics


Perrigo Company plc Ordinary Shares (PRGO)

Today's Latest Price: $42.58 USD

1.45 (-3.29%)

Updated Oct 28 7:00pm

Add PRGO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

PRGO Stock Summary

  • PRGO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 501.7 -- higher than 92.95% of US-listed equities with positive expected earnings growth.
  • PRGO's went public 28.88 years ago, making it older than 82.12% of listed US stocks we're tracking.
  • The volatility of PERRIGO Co plc's share price is greater than that of merely 6.07% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to PRGO, based on their financial statements, market capitalization, and price volatility, are HRC, BDC, CUB, AIMC, and WAB.
  • PRGO's SEC filings can be seen here. And to visit PERRIGO Co plc's official web site, go to www.perrigo.com.

PRGO Stock Price Chart Interactive Chart >

Price chart for PRGO

PRGO Price/Volume Stats

Current price $42.58 52-week high $63.86
Prev. close $44.03 52-week low $40.01
Day low $42.36 Volume 815,434
Day high $43.52 Avg. volume 1,018,861
50-day MA $47.85 Dividend yield 2.04%
200-day MA $52.24 Market Cap 5.81B

Perrigo Company plc Ordinary Shares (PRGO) Company Bio


Perrigo Company develops, manufactures, and distributes generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The company was founded in 1887 and is based in Dublin, Ireland.

PRGO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$42.58$27.7 -38%

Below please find a table outlining a discounted cash flow forecast for PRGO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that PERRIGO Co plc ranked in the 35th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of PERRIGO Co plc, consider:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 60. Its equity weight surpasses that of only 21.17% of free cash flow generating stocks in the Healthcare sector.
  • Its compound free cash flow growth rate, as measured over the past 5.5 years, is -0.07% -- higher than merely 17.15% of stocks in our DCF forecasting set.
  • PERRIGO Co plc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 7.32% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-39%
1%-39%
2%-38%
3%-38%
4%-37%
5%-36%

CRL, ENDP, GSK, CMD, and MOH can be thought of as valuation peers to PRGO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


PRGO Latest News Stream


Event/Time News Detail
Loading, please wait...

PRGO Latest Social Stream


Loading social stream, please wait...

View Full PRGO Social Stream

Latest PRGO News From Around the Web

Below are the latest news stories about PERRIGO Co plc that investors may wish to consider to help them evaluate PRGO as an investment opportunity.

Topical Antibiotic Pharmaceuticals Market Poised for Strong Growth Worldwide by 2020-2025 | Spotlight on Top Vendors Like Teva, Perrigo, Taro, Pfizer, Glenmark, GSK, Fera and Watson

The growing demand for Topical Antibiotic Pharmaceuticals has provided a major boost to the Global Topical Antibiotic Pharmaceuticals Market as more people are shifting their preferences to this growing sector. The market is expected to keep rising at a high

OpenPR | October 1, 2020

Tinea Pedis Treatment Market Anticipated to Grow Rapidly During 2027 - Bausch Health, GlaxoSmithKline, Novartis AG, Aqua Pharmaceuticals, Bayer AG and Perrigo Company

A new market report by The Insight Partners on the Tinea Pedis Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis

OpenPR | September 30, 2020

Actinic Keratosis Treatment Market Segmented by Product, Top Manufacturers, Geography Trends & Forecasts to 2026(Novartis, Perrigo, LEO Pharma)

Los Angeles, United State, – – QY Research recently added a research report, Global Actinic Keratosis Treatment Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Actinic Keratosis Treatment market. It highlights

OpenPR | September 30, 2020

Cipla, Lupin may gain from Perrigo's drug recall, says Macquarie

Perrigo announced the voluntary nationwide recall of albuterol sulfate following complaints that some units may not dispense due to clogging. A definitive timeline for reintroduction has not been determined.

Economic Times India | September 18, 2020

Stocks Across Pharma, Auto and Other Sectors to Keep An Eye On

In the pharmaceutical sector, top Indian firms Cipla and Lupin can expect notable gains owing to the fresh setback to Perrigo Company.

CNN-News18 | September 18, 2020

Read More 'PRGO' Stories Here

PRGO Price Returns

1-mo -6.77%
3-mo -19.34%
6-mo -18.49%
1-year -19.39%
3-year -46.96%
5-year -71.49%
YTD -16.57%
2019 35.65%
2018 -55.08%
2017 5.58%
2016 -42.14%
2015 -13.18%

PRGO Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full PRGO Dividend History

Continue Researching PRGO

Here are a few links from around the web to help you further your research on PERRIGO Co plc's stock as an investment opportunity:

PERRIGO Co plc (PRGO) Stock Price | Nasdaq
PERRIGO Co plc (PRGO) Stock Quote, History and News - Yahoo Finance
PERRIGO Co plc (PRGO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8146 seconds.